4.7 Article

Gut dysbiosis and neuroimmune responses to brain infection with Theiler's murine encephalomyelitis virus

期刊

SCIENTIFIC REPORTS
卷 7, 期 -, 页码 -

出版社

NATURE PORTFOLIO
DOI: 10.1038/srep44377

关键词

-

资金

  1. Red Espanola de Esclerosis Multiple (REEM) [RD 12/0008, RD16/0015/0021, RD 12/0032, RD 16/0015/0001, RD 12/0017, RD 16/0015/0004]
  2. Fondo de Investigacion Sanitaria (FIS) of the Instituto Nacional de Salud Carlos III
  3. Spanish Ministry of Economy and Competitiveness
  4. FIS [PI12-00239, PI13/205, SAF2013-42784R]
  5. Miguel Servet program of the FIS of the Ministry of Economy and Competitiveness of Spain [CP07/00146, CP13/00028, CB05/00137]

向作者/读者索取更多资源

Recent studies have begun to point out the contribution of microbiota to multiple sclerosis (MS) pathogenesis. Theiler's murine encephalomyelitis virus induced demyelinating disease (TMEV-IDD) is a model of progressive MS. Here, we first analyze the effect of intracerebral infection with TMEV on commensal microbiota and secondly, whether the early microbiota depletion influences the immune responses to TMEV on the acute phase (14 dpi) and its impact on the chronic phase (85 dpi). The intracranial inoculation of TMEV was associated with a moderate dysbiosis. The oral administration of antibiotics (ABX) of broad spectrum modified neuroimmune responses to TMEV dampening brain CD4(+) and CD8(+) T infiltration during the acute phase. The expression of cytokines, chemokines and VP2 capsid protein was enhanced and accompanied by clusters of activated microglia disseminated throughout the brain. Furthermore, ABX treated mice displayed lower levels of CD4(+) and CD8(+) T cells in cervical and mesenteric lymph nodes. Increased mortality to TMEV was observed after ABX cessation at day 28pi. On the chronic phase, mice that survived after ABX withdrawal and recovered microbiota diversity showed subtle changes in brain cell infiltrates, microglia and gene expression of cytokines. Accordingly, the surviving mice of the group ABX-TMEV displayed similar disease severity than TMEV mice.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Editorial Material Clinical Neurology

Multiple sclerosis progression: time for a new mechanism-driven framework

Tanja Kuhlmann, Marcello Moccia, Timothy Coetzee, Jeffrey A. Cohen, Jorge Correale, Jennifer Graves, Ruth Ann Marrie, Xavier Montalban, V. Wee Yong, Alan J. Thompson, Daniel S. Reich

Summary: Traditionally, multiple sclerosis has been categorized into distinct clinical descriptors, but accumulating evidence suggests that it should be considered as a continuum with varying pathophysiological processes. A shift from acute injury to inflammation and neurodegeneration contributes to the progressive course, along with decreased neural resilience due to aging. Understanding the key mechanisms and quantifying progressive pathology can have implications for clinical care, treatment targets, and regulatory decisions.

LANCET NEUROLOGY (2023)

Article Clinical Neurology

Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS Trial

Amit Bar-Or, Xavier Montalban, Xixi Hu, Harald Kropshofer, Petra Kukkaro, Neva Coello, Inga Ludwig, Roman Willi, Martin Zalesak, Krishnan Ramanathan, Bernd C. Kieseier, Dieter A. Haring, Morten Bagger, Edward Fox

Summary: This study aimed to explore the temporal association between serum neurofilament light chain (sNfL) and subclinical disease activity in relapsing multiple sclerosis (RMS) patients. The results showed that high baseline sNfL levels increased the risk of clinical relapse or Gd + T1 activity. Individual patient trajectories revealed a correlation between baseline sNfL levels and the development of Gd + T1 lesions.

NEUROLOGY AND THERAPY (2023)

Article Clinical Neurology

Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs

Enric Monreal, Jose Ignacio Fernandez-Velasco, Maria Isabel Garcia-Sanchez, Susana Sainz de la Maza, Sara Llufriu, Roberto Alvarez-Lafuente, Bonaventura Casanova, Manuel Comabella, Lluis Ramio-Torrenta, Jose Enrique Martinez-Rodriguez, Luis Brieva, Albert Saiz, Sara Eichau, Jose Maria Cabrera-Maqueda, Noelia Villarrubia, Mercedes Espino, Francisco Perez-Miralles, Xavier Montalban, Mar Tintore, Ana Quiroga-Varela, Maria Inmaculada Dominguez-Mozo, Fernando Rodriguez-Jorge, Juan Luis Chico-Garcia, Daniel Lourido, Jose Carlos Alvarez-Cermeno, Jaime Masjuan, Lucienne Costa-Frossard, Luisa Maria Villar

Summary: This multicenter cohort study found that high serum neurofilament light chain (sNfL) values obtained within the first year of disease were associated with long-term disability worsening in patients with multiple sclerosis (MS), suggesting that sNfL level measurement may help identify optimal candidates for highly effective disease-modifying treatments.

JAMA NEUROLOGY (2023)

Article Clinical Neurology

Validation of the Spanish version of DYsphagia in MUltiple Sclerosis questionnaire (DYMUS)

Marta Renom, Ingrid Galan, Xavier Vidal, Mireia Aldevert, Gemma Curto, Patricia Feliu, Itziar Garcia, Lorena Gonzalo, Xavier Sibera, Elisenda Anglada, Roger Meza, Montserrat Garcia, Victor Najas, Neus Mongay-Ochoa, Maria Jesus Arevalo, Angela Vidal-Jordana, Mar Tintore, Helena Bascunana, Xavier Montalban, Rosa Terre, Jaume Sastre-Garriga

Summary: The aim of this study was to translate and validate the Dysphagia in Multiple Sclerosis Questionnaire (DYMUS) in Spanish. The questionnaire was filled out by 100 patients with multiple sclerosis, and the results showed that the DYMUS scale is not sufficiently useful to detect dysphagia in this population. However, it can be helpful as a screening tool when combined with other measures.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2023)

Article Clinical Neurology

Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study

Serena Ruggieri, Luca Prosperini, Sarmad Al-Araji, Pietro Osvaldo Annovazzi, Alvino Bisecco, Olga Ciccarelli, Nicola De Stefano, Massimo Filippi, Vinzenz Fleischer, Nikos Evangelou, Christian Enzinger, Antonio Gallo, Afagh Garjani, Sergiu Groppa, Shalom Haggiag, Michael Khalil, Matteo Lucchini, Massimiliano Mirabella, Xavier Montalban, Carlo Pozzilli, Paolo Preziosa, Jordi Rio, Maria A. Rocca, Alex Rovira, Maria L. Stromillo, Mauro Zaffaroni, Carla Tortorella, Claudio Gasperini

Summary: Early relapses and substantial MRI activity in the first year of treatment are associated with worse short-term outcomes in patients treated with some of the oral DMTs.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Article Clinical Neurology

Views of Multiple Sclerosis Patients About Key Elements for a Decision Aid: A Qualitative Study

Miguel-Angel Robles-Sanchez, Montse Moharra, Cristina Bosch-Farre, Maria Jose Hernandez-Leal, Xavier Montalban, Jaume Sastre-Garriga, Lluis Ramio-Torrenta, Carme Bertran-Noguer

Summary: This qualitative study aimed to identify the key elements from the perspective of patients with relapsing-remitting multiple sclerosis (MS) to create a patient decision aid in the Spanish sociocultural context. The study found that patients have needs in information access, knowledge of available treatment options, and their decision-making role. These findings provide valuable information for designing and developing a patient decision aid to improve understanding and facilitate shared decision making between nurses and patients.

JOURNAL OF NEUROSCIENCE NURSING (2023)

Correction Clinical Neurology

Longitudinal stability of inter-eye differences in optical coherence tomography measures for identifying unilateral optic nerve lesions in multiple sclerosis (vol 453, 120695,2023)

Sachi A. Patil, Binu Joseph, Paula Tagliani, Jaume Sastre-Garriga, Xavier Montalban, Angela Vidal-Jordana, Steven L. Galetta, Laura J. Balcer, Rachel C. Kenney

JOURNAL OF THE NEUROLOGICAL SCIENCES (2023)

Article Health Care Sciences & Services

Assessment of Upper Extremity Function in Multiple Sclerosis: Feasibility of a Digital Pinching Test

Jennifer S. Graves, Marcin Elantkowski, Yan-Ping Zhang, Frank Dondelinger, Florian Lipsmeier, Corrado Bernasconi, Xavier Montalban, Luciana Midaglia, Michael Lindemann

Summary: The Pinching Test serves as a remote tool to assess upper extremity function in MS patients and can complement standard clinical evaluations.

JMIR FORMATIVE RESEARCH (2023)

Article Neuroimaging

Deciphering multiple sclerosis disability with deep learning attention maps on clinical MRI

Llucia Coll, Deborah Pareto, Pere Carbonell-Mirabent, Alvaro Cobo-Calvo, Georgina Arrambide, Angela Vidal-Jordana, Manuel Comabella, Joaquin Castillo, Breogan Rodriguez-Acevedo, Ana Zabalza, Ingrid Galan, Luciana Midaglia, Carlos Nos, Annalaura Salerno, Cristina Auger, Manel Alberich, Jordi Rio, Jaume Sastre-Garriga, Arnau Oliver, Xavier Montalban, Alex Rovira, Mar Tintore, Xavier Llado, Carmen Tur

Summary: The application of convolutional neural networks (CNNs) to MRI data is a promising approach for accurate prediction of neurological conditions. The study of CNN-derived attention maps can uncover key disease mechanisms.

NEUROIMAGE-CLINICAL (2023)

Meeting Abstract Clinical Neurology

Clinical outcomes with evobrutinib in relapsing MS up to 4 years of treatment: an ongoing Phase 2 open-label extension

X. Montalban, D. Arnold, M. Weber, K. Piasecka-Stryczynska, D. Tomic, A. Kinkolykh, Y. Li, H. Guehring, J. Wolinsky

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Meeting Abstract Clinical Neurology

Remibrutinib: A Novel BTKi in Development for MS With a Favorable Safety Profile in Various Autoimmune Disorders

L. Airas, M. Williams, T. Chitnis, S. Saini, M. Hide, G. Sussman, J. Nakahara, R. Bermel, T. Dorner, B. Loop, M. Ziehn, R. Willi, B. Kieseier, I. Nikolaev, S. Haemmerle, A. Zharkov, R. Siegel, B. Cenni, H. Wiendl, M. Maurer, A. Gimenez-Arnau, X. Montalban

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Meeting Abstract Clinical Neurology

Immune Response Following COVID-19 Vaccination (mRNA or Non-mRNA) in Evobrutinib-treated Patients with RMS: An Update

A. Bar-Or, A. H. Cross, A. Cunningham, Y. Hyvert, A. Seitzinger, E. E. Drouin, N. Alexandri, D. Tomic, X. Montalban

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Meeting Abstract Clinical Neurology

Blood Biomarker Dynamics in Highly Active Relapsing Multiple Sclerosis Patients Treated With Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study

H. Wiendl, N. De Stefano, F. Barkhof, X. Montalban, A. Achiron, T. Derfuss, A. Chan, S. Hodgkinson, A. Prat, L. Leocani, K. Schmierer, F. Sellebjerg, P. Vermersch, H. Jin, E. Jaervinen, A. Chudecka, L. Gardner

MULTIPLE SCLEROSIS JOURNAL (2023)

Meeting Abstract Clinical Neurology

Immune Response Following COVID-19 Vaccination (mRNA or Non-mRNA) In Patients with Relapsing Multiple Sclerosis Treated with the Bruton's Tyrosine Kinase Inhibitor Evobrutinib: An Update

A. Bar-Or, A. H. Cross, A. Cunningham, Y. Hyvert, A. Seitzinger, E. E. Drouin, N. Alexandri, D. Tomic, X. Montalban

MULTIPLE SCLEROSIS JOURNAL (2023)

Meeting Abstract Clinical Neurology

Neurofilament Light Chain Levels and Disease Activity During Long-Term Treatment of Relapsing Multiple Sclerosis with the Bruton's Tyrosine Kinase Inhibitor Evobrutinib

J. Kuhle, L. Kappos, X. Montalban, P. Benkert, Y. Li, K. Thangavelu, Y. Hyvert, D. Tomic

MULTIPLE SCLEROSIS JOURNAL (2023)

暂无数据